Capricor Therapeutics Inc
Change company Symbol lookup
Select an option...
CAPR Capricor Therapeutics Inc
MSFT Microsoft Corp
XOM Exxon Mobil Corp
CSCO Cisco Systems Inc
MRVL Marvell Technology Group Ltd
DHT DHT Holdings Inc
DLNG-A Dynagas LNG Partners LP
EEX Emerald Holding Inc
APEN Apollo Endosurgery Inc
TUP Tupperware Brands Corp
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

Price
Delayed
$5.40
Day's Change
0.0099 (0.18%)
Bid
--
Ask
--
B/A Size
--
Day's High
5.74
Day's Low
5.39
Volume
(Light)

Today's volume of 697,754 shares is on pace to be much lighter than CAPR's 10-day average volume of 2,770,922 shares.

697,754

Company Profile

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
80.07x
Price/Book (MRQ)
5.16x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

April 2020
Current Month
311.9K
Previous Month
73.9K
Percent of Float
2.76%
Days to Cover
0.0162 Days

Share Information

CAPR is in a share class of common stock
Float
11.3M
Shares Outstanding
14.3M
Institutions Holding Shares
19
3.32%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Frank I. LitvackChmn.
  • Linda MarbanPres.
  • Anthony BergmannCFO
  • Karen G. KrasneyExec.VP
  • Thomas Lyle CopmannVP

Address

  • 8840 Wilshire Blvd Fl 2
  • Beverly Hills, CA 90211-2606
  • Phone: (310) 358-3200
  • Fax: (302) 655-5049
  • http://capricor.com/

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.